Mega Genomics Ltd. provided a quarterly update on its business operations and resumption progress. The company reported that it continues to operate as usual in all material aspects despite the ongoing suspension of trading of its shares since 1 April 2025. As of 30 November 2025, Mega Genomics has collaborated with healthcare institutions in over 340 cities across China and has performed over 25 million genetic tests in total. The company is principally engaged in providing consumer genetic testing services and cancer screening services. Mega Genomics also announced the completion of an independent forensic investigation, with the Investigation Committee and the Board expressing satisfaction with the findings. Trading in the company's shares remains suspended until further notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mega Genomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11973740), on December 31, 2025, and is solely responsible for the information contained therein.